Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Journal of Clinical Medicine|June 12, 2026
Impact of Body Mass Index on Clinical Outcomes of LLETZChiara Paternostro, Elmar Joura, Magdalena Postl, et al.Journal of Gynecologic Oncology|November 13, 2020
The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancerThomas Bartl, Christine Bekos, Magdalena Postl, et al.Journal of Personalized Medicine|June 27, 2024
Oncologic and Obstetric Outcomes Following Radical Abdominal Trachelectomy in Non-Low-Risk Early-Stage Cervical Cancers: A 10-Year Austrian Single-Center ExperienceMelina Danisch, Marlene Kranawetter, Thomas Bartl, et al.Journal of Personalized Medicine|November 26, 2025
Novel Treatment Concepts for Cervical Cancer-Moving Towards Personalized TherapyMelina Danisch, Magdalena Postl, Thomas Bartl, et al.Cancers|October 16, 2024
The Predictive Value of the Fibrinogen-Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian CancerMagdalena Postl, Melina Danisch, Fridolin Schrott, et al.Scientific Reports|August 2, 2019
Prognostic value of serum creatine level in patients with vulvar cancerRichard Schwameis, Magdalena Postl, Christine Bekos, et al.Cancers|March 13, 2025
ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian CancerValentina Glueck, Christoph Grimm, Magdalena Postl, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 5, 2026
Clinical relevance of CA125 in low-grade serous ovarian cancer: a retrospective multi-center JAGO/NOGGO studyChiara Flethe, Mina Netkova-Heintzen, Magdalena Postl, et al.Cancers|April 3, 2021
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer PatientsThomas Bartl, Jasmine Karacs, Caroline Kreuzinger, et al.Pageof 1